Latest Filings

Issuer Activity

Overview :: CVS Caremark Corporation (N:CVS) [?]
Business Focus: Drug Retailers Share on StockTwits
Recent Price for CVS
USD 79.450 +0.020 (+0.025%)
NYSE Delayed 15 minutes
Aug 29 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
79.800 79.820 19.46 2,416,170 92,162.00
1-Day Low 52-Week Low Yield Avg. Volume  
79.280 56.320 1.4% NYSE  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for CVS within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:18pm ET August 29th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Aug 7/14 Aug 6/14 Joyner J. David Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -45,897  
Aug 7/14 Aug 6/14 Joyner J. David Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -77,619  
Aug 7/14 Aug 6/14 Joyner J. David Direct Ownership Common Stock S - Open market or private sale -45,897 $76.10
Aug 7/14 Aug 6/14 Joyner J. David Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 45,897 $36.23
Aug 7/14 Aug 6/14 Joyner J. David Direct Ownership Common Stock S - Open market or private sale -77,619 $76.10
Aug 7/14 Aug 6/14 Joyner J. David Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 77,619 $28.10
Jul 22/14 Jul 21/14 Boratto Eva C Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -22,107  
Jul 22/14 Jul 21/14 Boratto Eva C Direct Ownership Common Stock S - Open market or private sale -22,107 $76.77
Jul 22/14 Jul 21/14 Boratto Eva C Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 22,107 $30.16
Jul 3/14 Jul 1/14 Denton David M Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -48,178  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for CVS within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:18pm ET August 29th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Aug 7/14 Aug 6/14 Joyner J. David Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -45,897  
Aug 7/14 Aug 6/14 Joyner J. David Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -77,619  
Aug 7/14 Aug 6/14 Joyner J. David Direct Ownership Common Stock S - Open market or private sale -45,897 $76.10
Aug 7/14 Aug 6/14 Joyner J. David Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 45,897 $36.23
Aug 7/14 Aug 6/14 Joyner J. David Direct Ownership Common Stock S - Open market or private sale -77,619 $76.10
Aug 7/14 Aug 6/14 Joyner J. David Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 77,619 $28.10
Jul 22/14 Jul 21/14 Boratto Eva C Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -22,107  
Jul 22/14 Jul 21/14 Boratto Eva C Direct Ownership Common Stock S - Open market or private sale -22,107 $76.77
Jul 22/14 Jul 21/14 Boratto Eva C Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 22,107 $30.16
Jul 3/14 Jul 1/14 Denton David M Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -48,178  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Consumer Non-Cyclicals Industry:  Drug Retailers
 
See Regulatory Filings on SEC
Key People
David W. Dorman
Independent Chairman of the Board
Jonathan C. Roberts
Executive Vice President; President of CVS Caremark Pharmacy Services
Larry J. Merlo
President, Chief Executive Officer, Director
David M. Denton
Chief Financial Officer, Executive Vice President
Lisa G. Bisaccia
Chief Human Resource Officer, Senior Vice President
Thomas M. Moriarty
Executive Vice President, General Counsel
Troyen A. Brennan
Executive Vice President, Chief Medical Officer
Helena B. Foulkes
Executive Vice President, President of CVS/pharmacy
J. David Joyner
Executive Vice President
Per G. H. Lofberg
Executive Vice President
   
Company Contact
Address: One CVS Drive
WOONSOCKET RI 02895
Tel: 1-800-2010938
Website: info.cvscaremark.com
IR: phx.corporate-ir.net/phoenix.zhtml?c=99533&p=irol-irhome
Business Overview
CVS Caremark Corporation (CVS Caremark), together with its subsidiaries, is a pharmacy health care provider in the United States. CVS Caremark provides pharmacy services through its pharmacy benefit management (PBM), mail order and specialty pharmacy division, CVS Caremark Pharmacy Services; approximately 7,300 CVS/pharmacy retail stores; retail-based health clinic subsidiary, MinuteClinic, and its online retail pharmacy, CVS.com. The Company operates in three business segments: Pharmacy Services, Retail Pharmacy and Corporate. Its corporate segment provides management and administrative services. The Corporate segment consists of certain aspects of its executive management, corporate relations, legal, compliance, human resources, corporate information technology and finance departments. In January 2014, Cvs Caremark Corporation completed the acquisition of Coram LLC, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc.
Financial Overview
For the six months ended 30 June 2014, CVS Caremark Corporation revenues increased 9% to $67.29B. Net income before extraordinary items increased 14% to $2.38B. Revenues reflect Pharmacy Services Segment increase of 13% to $42.03B, Retail Pharmacy Segment increase of 4% to $33.35B, Comp. Store Sales (Growth - %) - Pharmay increase from -0.7 to 4.4%, Retail Sales-Retail Pharmacy increase of 4% to $33.35B.
Employees: 130,000 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $103,672M as of Jun 30, 2014
Annual revenue (TTM): $132,041M as of Jun 30, 2014
EBITDA (TTM): $10,486M as of Jun 30, 2014
Net annual income (TTM): $4,897M as of Jun 30, 2014
Free cash flow (TTM): $3,048M as of Jun 30, 2014
Net Debt Last Fiscal Year: $11,659M as of Jun 30, 2014
Shares outstanding: 1,160,000,000 as of Jun 30, 2014
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Express Scripts Holding C (OQ:ESRX)
McKesson (N:MCK)
Cardinal Health (N:CAH)